The recommendation follows clinical evidence from two Phase 3 trials, which showed PEDMARQSI could reduce the risk of hearing loss by about 50% in children treated with cisplatin. Hearing loss is a ...
The recommendation follows clinical evidence from two Phase 3 trials, which showed PEDMARQSI could reduce the risk of hearing loss by about 50% in children treated with cisplatin. Hearing loss is ...
A “groundbreaking” drug which helps to prevent hearing loss among children undergoing cancer treatment has been given the green light for NHS use. Chemotherapy drug cisplatin is widely used to ...